Edwards Lifesciences Corporation (NYSE:EW) – Research analysts at Jefferies Group lifted their FY2018 earnings per share (EPS) estimates for Edwards Lifesciences Corporation in a report released on Thursday. Jefferies Group analyst R. Denhoy now forecasts that the medical research company will earn $4.16 per share for the year, up from their previous estimate of $4.05. Jefferies Group has a “Buy” rating and a $132.00 price target on the stock.

Other research analysts have also recently issued research reports about the company. BidaskClub raised Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research cut Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. SunTrust Banks, Inc. increased their price target on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Barclays PLC increased their price target on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $120.89.

TRADEMARK VIOLATION WARNING: “Brokers Offer Predictions for Edwards Lifesciences Corporation’s FY2018 Earnings (EW)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/09/brokers-offer-predictions-for-edwards-lifesciences-corporations-fy2018-earnings-ew-updated.html.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 115.51 on Friday. The firm has a market cap of $24.31 billion, a PE ratio of 35.03 and a beta of 0.64. The stock’s 50 day moving average is $117.23 and its 200 day moving average is $104.08. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The business had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 earnings per share.

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Edwards Lifesciences Corporation by 2.5% in the first quarter. Vanguard Group Inc. now owns 20,341,668 shares of the medical research company’s stock valued at $1,913,541,000 after buying an additional 505,725 shares in the last quarter. BlackRock Inc. increased its stake in shares of Edwards Lifesciences Corporation by 2,184.9% in the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after buying an additional 13,390,818 shares in the last quarter. State Street Corp increased its stake in shares of Edwards Lifesciences Corporation by 1.7% in the first quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock valued at $883,219,000 after buying an additional 157,844 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Edwards Lifesciences Corporation by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after buying an additional 1,459,921 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Edwards Lifesciences Corporation by 17.4% in the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock valued at $539,685,000 after buying an additional 850,168 shares in the last quarter. 83.96% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Donald E. Bobo, Jr. sold 34,120 shares of the company’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $109.98, for a total transaction of $3,752,517.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $109.71, for a total value of $5,386,761.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 184,951 shares of company stock valued at $20,780,242. 2.13% of the stock is currently owned by company insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.